ELIMINATING CANCER HEALTH DISPARITIES
THROUGH RESEARCH, PREVENTION & QUALITY CARE
Moffitt Cancer Center was established in 1981 by the Florida Legislature to address the state’s cancer burden. The center was named after H. Lee Moffitt, former Speaker of the Florida House of Representatives, who worked tirelessly to influence legislation that established the facility. In 1977, Moffitt lost three friends to cancer – each of whom had to seek sophisticated cancer treatment outside of Florida. Among them was fellow attorney George Edgecomb, Hillsborough County’s first African American judge whose name now graces the county’s courthouse. Out of Moffitt’s sadness was born a resolve that would direct his efforts for years to come.

Moffitt has a long history of working to eliminate cancer health disparities, and we invite you to read this annual report’s special feature, summarizing some of our progress in this area. Initiatives include the creation of the George Edgecomb Society, named in memory of local African-American icon Judge George Edgecomb. The Society is generating community support and additional research funding to ensure equitable health outcomes and the elimination of cancer health disparities among blacks and African Americans. The feature also provides a glimpse into our outreach services, prevention and education programs, specialized clinical trials and key partnerships.

As you will read in the 2017 Highlights, numerous examples of Moffitt’s progress and commitment to excellence include:

- Brian J. Czerniecki, M.D., Ph.D., and colleagues developed a new dendritic cell-based vaccine to help early-stage breast cancer patients with HER2 positive disease.
- The National Heart, Lung and Blood Institute (NHLBI) selected Moffitt as a cell therapies processing facility to produce human cell-based therapies to help develop early-stage clinical trials to evaluate the safety and effectiveness of new therapies.
- One such immune cell therapy is TIL therapy, which can reprogram tumor infiltrating lymphocytes (TIL) outside of the body with drugs, wash all the drugs away and infuse massive numbers of only those TIL cells (cancer killers) back into the patient.
- NBC News and CBS News featured national reports on Moffitt’s Frederick Locke, M.D., principal investigator for clinical trials using CAR T, another immunotherapy that engineers a patient’s own immune cells to target and fight cancer. The FDA approved CAR T to treat certain pediatric and young adult patients with a form of acute lymphoblastic leukemia, and Moffitt will be a certified treatment center. And another CAR T therapy for adults with large B cell lymphoma is under FDA review.

The cancer center has welcomed new leaders in the last year as it plans for physical expansion to meet the growing needs of our patient care and research enterprise. Moffitt unveiled an $800 million expansion plan that is expected to take 10 years to complete, with the first phase – a new clinical support building – beginning in 2017. A new research facility and renovations to existing buildings will follow. Additionally, Moffitt purchased a 21-acre parcel of land across the street from the McKinley Campus. Having this site will allow the cancer center to explore future expansion options.

We hope you enjoy reading this annual report, because we believe it reflects the heart of Moffitt and offers a glimpse into the many endeavors that are making a difference to prevent and cure cancer here in the Tampa Bay community, the state and beyond. We look forward to what together we will accomplish in 2018 and the years ahead.
COVER FEATURE STORY

SHARE UNIFIED FOCUS

ELIMINATING CANCER HEALTH DISPARITIES IS DEEPLY ROOTED IN MOFFITT MISSION

Moffitt Cancer Center’s commitment to eliminate cancer health disparities is deeply rooted in its overall mission to contribute to the prevention and cure of cancer. Many initiatives created in the early years continue today, while even more efforts are being established.

PARTNERSHIPS IMPROVE HEALTH OF UNDERSERVED COMMUNITIES

“Giving a voice to those who don’t have one...and once they get that voice, empower them to use it,” says Margarita Romo of Farmworkers Self-Help, Inc. (FSH), the non-profit she founded in 1982. FSH, headquartered in one of Pasco County’s poorest communities, was one of the first partners to join the Tampa Bay Community Cancer Network (TBCCN) through Moffitt Cancer Center. And there is no measuring how many lives have been saved through this alliance.

The Tampa Bay Community Cancer Network (TBCCN) is a collaborative network that creates and implements community-based partnerships with health centers, non-profit organizations, faith-based groups, adult education, literacy groups and Moffitt Cancer Center. Mutual goals are to create and implement effective community-based interventions to impact cancer disparities in the Tampa Bay area.

Romo is relentless in her aim to better the lives of seasonal and migrant farmworkers with education, advocacy and organizing. She says at one time the people FSH serves may not have even heard of Moffitt, and if they had, it was an “unreachable” place, certainly not available to them. Now they see the cancer center as a place of hope for their cancer-related health issues. And once attitudes are changed toward institutions that provide medical care and promote healthy habits, “we’re going to save a lot more lives,” Romo says. “They’re training us on how to take responsibility for our own health. This is how you change the system. And it’s starting right here, right now. I’m just so happy to be part of it.”

TBCCN was initially funded in 2005 by a grant from the National Cancer Institute (NCI) as one of its 25 Community Networks Programs with the goal of creating and implementing sustainable, effective community-based interventions to impact cancer disparities in the Tampa Bay area.

Under the auspices of TBCCN, Moffitt researcher Cathy Meade, Ph.D., R.N., continues to champion efforts to build community partnerships for better health, established on the principle of community-based participatory research. This approach allows the stakeholders - which include Farmworkers Self-Help, Inc., Tampa Family Health Centers, The Florida Departments of Health-Pinellas, Hillsborough and Pasco Counties, and more - to define the priorities and inform the approach. Today, TBCCN includes 28 partners.

“Giving a voice to those who don’t have one...”

Physicians and Scientists

Dr. Meade’s research and education interests involve finding innovative ways to impact health disparities, producing culturally and literacy relevant cancer communications and creating sustained community-based education and outreach initiatives for medically underserved populations. She has served in NCI work groups designed to increase awareness of the impact of literacy in healthcare. Additionally, her work focuses on developing cancer training programs that increase the number of underrepresented scientists.

MOFFITT DIVERSITY ENRICHES PATIENT EXPERIENCE

In 2003 the cancer center established Moffitt Diversity, under the leadership of B. Lee Green, Ph.D. The aims include promoting cancer prevention education among diverse communities.

“Moffitt Diversity fosters a positive and empowering environment for our faculty and staff and improves the experience for our patients and their families,” said Moffitt President and CEO Alan List, M.D. “This is achieved by promoting cultural and linguistic competence, increasing patient safety, enhancing patient satisfaction, ensuring the highest quality care for all individuals and improving healthcare outcomes.”

“At Moffitt Cancer Center, we seek to create and foster an environment where everyone can enter the doors and feel confident that they will receive the best state-of-the-art, compassionate cancer care in the nation,” said Dr. Green, vice president, Diversity, Public Relations and Strategic Communications for Moffitt and senior member, Health Outcomes and Behavior. “This is why we continue to build and renew our commitment to promoting diversity and equality throughout our cancer care, research, education and employment.”

COMMUNITY BENEFIT EFFORTS SERVE HIGH-RISK POPULATIONS

Moffitt Cancer Center’s Community Benefit Initiative supports patients, families and clinicians through advancing cancer prevention, early detection, clinical care and research, especially for those at-risk populations disproportionately impacted by cancer.

As required by the Patient Protection and Affordable Care Act of 2010, Moffitt conducts a community health needs assessment every three years and adopts an implementation strategy to meet the identified needs. In 2016 Moffitt conducted its second such assessment and identified the most pressing needs within our community. We are meeting key needs from this most recent assessment of 1) screening and prevention and 2) access to care, through our prevention, early detection and screening programs.

M-POWER PROVIDES PATIENT ACCESS AND NAVIGATION

For people like Elba Nieves, M-POWER [Moffitt Program for Outreach Wellness Education and Resources] facilitates access to life-saving screening and prevention services. Nieves got a voucher for her mammogram through M-POWER, and at Moffitt McKinley Outpatient Center an interpreter from Moffitt’s Language Services helped her. Nieves says the interpretation services boosted her confidence when going in for the mammogram procedure.

M-POWER: Moffitt Program for Outreach Wellness Education and Resources

For people like Elba Nieves, M-POWER facilitates access to screening, prevention and care.

“At Moffitt Cancer Center, we seek to create and foster an environment where everyone can enter the doors and feel confident that they will receive the best state-of-the art, compassionate cancer care in the nation.”
Fortunately, Nieves had a good outcome. Her mammogram results were negative. For people who test positive, their cancers are easier to cure because they were detected early.

M-POWER is directly involved in our community benefit efforts by offering health education in the areas of prevention, early detection, and screening, delivered through a range of programs designed specifically for underserved communities.

**ORIGINAL CALL TO COMMUNITY EDUCATION AND OUTREACH, M-POWER BEGAN IN 1999.**

M-POWER is part of Moffitt Diversity, with a focus on increasing access to care. This is achieved by enhancing Moffitt’s image among underserved communities as an organization delivering culturally and linguistically competent care through prevention education and mutually beneficial partnerships.

The aim is to serve as a resource, as well as to identify opportunities to increase Moffitt’s preparedness when serving diverse communities. One of the program’s hallmark events, the annual Men’s Health Forum, serves a growing number of men in our community without access to regular health care services.

**BRIDGING THE COMMUNICATION GAP**

If communication is a two-way street, Moffitt Language Services is a bridge to ensure equity in care. Patients and families separated from their caregiving team by a difference in language rely on Moffitt’s professional translators, medical interpreters and over-the-phone and video remote interpretation services every day of the year.

And for patients like Vernon Hudson, who are Deaf, Moffitt Language Services arranges with a vendor to have an American Sign Language (ASL) interpreter meet the patient and handle the necessary interpretation during the visit.

The experience for Hudson is seamless, says Prada Antionello, manager, Moffitt Language Services. Language services receives an alert when a patient has an appointment and then works with an agency that sends an ASL interpreter. There are about 30 Deaf patients being treated at Moffitt at any given time.

Moffitt sees patients from all 67 Florida counties, all 50 states and more than 130 foreign countries. The native languages spoken are as varied as Moffitt’s patient population – everything from Spanish to Vietnamese to Farsi to Akan.

In Fiscal Year 2017, Language Services logged 7,640 live medical interpreting encounters with Spanish-speaking patients; 3,348 took place via telephone interpreters, and 1,468 were conducted via video interpreting. Team members placed more than 686 translation requests for written documents through Moffitt’s online Language Services form.

**MOFFITT CANCER CENTER’S COMMITMENT TO THE LGBTQ COMMUNITY**

Moffitt’s commitment to diversity in patient access to care and research, in our workplace, and in vendor relations includes supportive LGBTQA policies and team member training on issues unique to this community. Moffitt’s commitment, embodied in our culture and demonstrated in the daily work of cancer center team members, is reflected by numerous awards outlined in the “Accolades and Recognitions” section of this annual report.

Moffitt’s care practices include clinics attuned to the unique needs of our LGBTQ patients, with specialized physicians like Julian Sanchez, M.D., chief of Moffitt’s Colorectal Surgery Program. His large clinical practice specializes in cancer treatment and screening for anal dysplasia, a precancerous condition that disproportionately affects gay men. Dr. Sanchez has developed community partnerships to extend this clinic’s reach, becoming a local screening partner.

Moffitt understands the power of research to ignite progress and change. Its Miles for Moffitt community fundraising events support important programs including the LGBTQ Miles for Moffitt, (MFM) Research Group led by Drs. Gwendolyn Quynn and Matthew Schabath. This group is actively involved in identifying both barriers and facilitators of cancer services to the LGBTQ population through a series of research studies, including the first comprehensive review and synthesis of published literature on LGBTQ and cancer incidence, mortality, quality of life, and survivorship issues. It appeared in one of the nation’s most influential peer-reviewed publications.

**MOFFITT RESEARCHERS STUDY POPULATIONS EXPERIENCING DISPARITIES**

Addressing cancer health disparities starts by understanding the unique aspects of any given population experiencing disproportionate burdens of the disease. Moffitt’s Population Science Research Division and its Health Outcomes and Behavior (HOB) Department work with large data sets, survey-based research and lab work across a variety of fields. They use data to assess a cancer’s potential to occur, grow and spread within a given population, or to find targets for new drugs. HOB researchers study behaviors that play a part in preventing, causing or managing cancer. Eliminating cancer health disparities is a goal that ties directly to such research.

Clement Gwede, Ph.D., MPH, R.N., focuses on identifying and reducing barriers that prevent underserved populations from adopting known cancer-fighting strategies. Colorectal cancer is a case in point. Its incidence and mortality are highest among blacks. Despite the proven life-saving potential of screening tools like inexpensive, easy to perform home stool sample test kits, this group consistently posts screening rates well below the national average. To reverse this trend, Dr. Gwede and his colleagues conducted community-wide research to identify both barriers and facilitators to screening, with a goal of using that information to develop more effective recruitment efforts.

**CLINICAL TRIALS FOCUS ON MINORITY ACCRUAL**

Dr. Green and Daniel Sullivan, M.D., associate center director, Clinical Science, co-chair Moffitt’s Minority Clinical Research Committee. The committee oversees clinical research focused on minorities, patient navigation, clinical research education, disparities health communications and also focuses on reaching minority populations within the cancer center’s catchment area.

In one such trial supported by the center, Dr. Yamoah is leading a validation study of the Decipher Biopsy test on treatment recommendations in African American and non-African American men with prostate cancer.

**Clinical trial participant Vernon Hudson relies on the services of an American Sign Language interpreter during his appointments at the cancer center.**
find whether an on and off schedule of taking abiraterone would prolong cancer response to the drug and maintain the patients’ ability to perform daily activities.

Claudio Anasetti, M.D., and Ernesto Ayala, M.D., of Moffitt’s Blood and Marrow Transplant and Cellular Immunotherapy Department, are studying a graft-versus-host disease regimen in patients following haploidentical peripheral blood stem cell grafts. The co-principal investigators are accruing minorities only on this Moffitt-supported clinical trial, because they want to increase the availability of transplants for minorities.

Such trials have many benefits. Not all patients respond to treatment the same way, notes Dr. Sullivan, and patients benefit from information gleaned from these trials that help determine personalized treatments. He cites as an example the US4 grant Moffitt has with Ponce Health Sciences University in Puerto Rico. Moffitt and Ponce researchers have done an analysis of lung cancer patients to find mutations that determine, in part, what drugs a patient should receive. They found that Hispanic/Latinos in Puerto Rico have different mutations from Caucasians and should be treated differently to assure better outcomes.

**PARTNERSHIP WITH PONCE YIELDS UNIQUE BIOBANK**

Jaileene Perez-Morales, a Ph.D. candidate in Biomedical Sciences at Ponce Health Sciences University is interning at Moffitt in the lab of Teresita Muñoz-Antonia, Ph.D., through the partnership between Moffitt and Ponce Health Sciences University.

Perez-Morales, from Aguadilla, Puerto Rico, is studying biomedical sciences, specifically lung cancer research, and after receiving her Ph.D., she wants to pursue additional training in immune oncology. Her long-term goal includes “working in a cancer research center that will provide her the opportunity to integrate different fields into my investigations.”

Through the Ponce Health Sciences University-Moffitt Cancer Center partnership, both institutions have forged a strong working relationship founded on seamless communication, mutual support and benefits. With resources and significant commitment from both institutions, the Partnership has established joint programs, enhancing basic and clinical research, enriching cancer outreach, expanding cancer education, and creating a unique Hispanic/Latino Biobank, the first functional, centralized Hispanic cancer-related biobank in Puerto Rico. This partnership has led to the development of a robust network and infrastructure necessary for a sustained long-term collaboration to improve cancer outcomes in the Hispanic/Latino population. The Partnership is funded by a National Cancer Institute US4 grant and is led at Moffitt by Drs. Muñoz-Antonia and Sullivan and at PHSU by Drs. Jaime Matta and Jose Torres.

While this annual report was in production, Puerto Rico was hit by two devastating hurricanes. As the report goes to press, we are reaching out to our partners there to determine their safety, the extent of the damage and what we need to do to help rebuild.

**LANDMARK FAMILY NAME SUPPORTS CANCER DISPARITIES RESEARCH**

The memory of George Edgecomb, Hillsborough County’s first African American judge whose name now graces the county’s courthouse is fueling the cancer center’s drive to address one of cancer’s most glaring inequities: the disproportionate toll it takes on the black community.

The launching of the George Edgecomb Society during fiscal year 2017 will further support the efforts of Moffitt’s physicians and researchers in their work to eliminate cancer health disparities.

The Society will educate Moffitt members on new treatment protocols and research efforts and award financial support for the research and clinical efforts of scientists focused on cancer disparities.

George’s widow and retired Hillsborough County School Board leader Doretha Edgecomb views the Society as a fitting tribute to her late husband. “George was always committed to making a positive impact wherever it was needed,” she says. “And if the impact of using his name brings attention to these disparities, saves lives and encourages research, then it’s the right thing to do.”

Moffitt researchers have undertaken major studies of both the biology and the behaviors behind cancer health disparities. Their investigations run the gamut: studying disparities in breast and cervical cancer, looking into the role of HPV in various diagnoses, developing culturally- and literacy-relevant cancer communications, and examining the impact of disproportionate minority participation in clinical trials.

Funds generated through the Edgecomb Society will have a meaningful impact for disparities researchers to put into action strategies that can reduce and, ultimately, eliminate cancer health disparities, notes Dr. Green. Such work is crucial - and often in need of a funding source like the Edgecomb Society. “Our goal is to get funding into the hands of our disparities researchers, so that we can put into action strategies that can reduce and eventually eliminate disparities altogether.”

Moffitt continues to strengthen and aims to redouble its efforts to eliminate cancer health disparities at the cancer center, in the Tampa Bay area and beyond.

Summarizing our initiatives in the words of Margarita Romo, George’s widow and retired Hillsborough County School Board leader, “We’re accomplished a lot, and we see improvements in so many areas. But there really is no time to sit still and pat ourselves on the backs. We’ve got so much more to do.”

Left to right: Dr. Alan List, Valerie Goddard, Doretha Edgecomb, Vivica A. Fox, H. Lee Moffitt, Dr. Lee Green
Moffitt Cancer Center’s Community Benefit initiative supports patients, families and clinicians through advancing cancer prevention, early detection, clinical care and research, especially for those at-risk populations disproportionately impacted by cancer.

**Total Community Benefit Dollars:**

$71,655,856

- **Charity Care**
  - Total cost of services incurred by Moffitt to provide medical services to patients who are unable to pay
  - $18,637,487

- **Community Benefit Operations**
  - Costs associated with assigned staff, community health needs and assessments
  - $149,984

- **Community Health Improvement Activities**
  - Cost of programs that address the root causes of health problems, including expenses for the development of community-building programs and partnerships
  - $55,279

- **Health Professions Education**
  - Cost associated with clinical education and training for physicians and medical students not including government funding
  - $9,626,894

- **Medicaid Shortfalls**
  - The Medicaid program pays Moffitt less than it costs the organization to provide care to its Medicaid patients.
  - $9,703,460

- **Research**
  - Clinical and community health research, as well as general health care delivery studies shared with the public and funded by the government or a tax-exempt entity
  - $32,714,327

- **Community Building Activities**
  - Cost of programs that address the root causes of health problems, including expenses for the development of community-building programs and partnerships
  - $55,279

**Access to Care**

1) **Improve access to health care services for those in need within the primary service area**
   - An online Community Resource Directory was developed for Moffitt team members to have a centrally located source of information to use when navigating patients and community members in need of services. The Directory is a comprehensive collection of community-based services and resources that are categorized by agency name, county and resource type (i.e., transportation, social services, seniors, cancer, etc.).

2) **Provide increased navigation services for patients and community members**
   - A Community Navigator was hired as part of a pilot, one-year grant. The Community Navigator assisted 48 community members with scheduling appointments at Moffitt, Requesting Language Services, coordinating transportation, lodging and other needs for accessing cancer screening and treatment.
   - Two full-time, internal Patient Navigators who are registered nurses were hired in April 2017 to assist patients in the Adolescent and Young Adult Sarcoma Clinic and the Head and Neck Clinic.

**Screening and Prevention Services**

1) **Increase awareness and education of cancer prevention and screening**
   - Public Service Announcements (PSAs) have been filmed to promote cancer screening for breast, lung, colorectal, and prostate cancer. Celebrities Vivica A. Fox and Paul Anthony, and NFL star Derrick Brooks, right, were spokespersons for the PSAs.
   - 160 community events, educational workshops, and Facebook Live events have been implemented to educate the community about cancer prevention and screenings.

2) **Provide increased and/or improved screening and prevention services for lung cancer, breast cancer, prostate cancer and colorectal cancer**
   - A limited number of screening vouchers for uninsured patients that qualify will be offered each year. The process of scheduling appointments, estimating costs and partnering with community clinics were determined throughout Fiscal Year 2017.

* A full report of the 2016-2019 Implementation Plan can be found on Moffitt’s website at https://moffitt.org/publications/community-benefit
Moffitt has made a lasting commitment to the prevention and cure of cancer, working tirelessly in the areas of patient care, research and education - offering a level of service that stands above the rest.

**2017 PATIENT CARE ORIGIN**
- Hillsborough: 30%
- Pasco: 10%
- Pinellas: 12%
- Polk: 6%
- Manatee: 4%
- Hernando: 3%
- Sarasota: 3%
- Other Florida: 28%
- Non-Florida: 4%

**2017 PATIENT CARE VOLUMES**
- Beds: 206
- New Patients: 21,701
- Outpatient Visits: 384,857
- Admissions: 9,210
- Surgical Cases: 10,420
- Patients seen: 60,426

**2017 PATIENT CARE ORIGIN**
- Commercial: 1%
- HMO/PPO: 42%
- Medicaid: 2%
- Medicaid Managed Care: 4%
- Medicare: 35%
- Medicare Managed Care: 12%
- Other: 3%
- Private Pay: 1%

**2017 PAYER MIX**

---

MOFFITT UNVEILS $800 MILLION EXPANSION
The $800 million expansion plan is expected to take 10 years to complete, with the first phase – a new clinical support building – beginning in 2017. A new research facility and renovations to existing buildings will follow.

MOFFITT ACQUIRES LAND ACROSS FROM MCKINLEY CAMPUS
Moffitt purchased a 21-acre parcel of land across the street from the McKinley Campus. Having this site will allow the cancer center to explore options to implement future expansion, allowing for the most effective use of space on the Magnolia Campus.

STATE EXTENDS CIGARETTE TAX FUNDING
Moffitt Cancer Center’s excellent partnership with the State continued this year. Our current level of cigarette tax funds were extended from 2033 to 2053. We also saw an increase in research funds for pediatric studies and statutory creation of the Medicinal Cannabis Research & Education Coalition. This Coalition will examine the efficacy of medical marijuana and provide recommendations to the Legislature and Executive Branch regarding policy and legislation surrounding the issue.

GEORGE EDGECOMB SOCIETY SUPPORTS CANCER DISPARITIES RESEARCH
The newly created George Edgecomb Society at Moffitt is addressing the disproportionate toll cancer takes on the black/African American community. As federal research dollars continue to decline, this new fundraising initiative aims to further engage those most impacted by these disparities.

CAR T REVOLUTIONIZES CANCER TREATMENT
NBC News and CBS News national reports featured Moffitt’s Frederick Locke, MD, the principal investigator for clinical trials using CAR T, an experimental immunotherapy that engineers a patient’s own immune cells to target and destroy their cancer. One of five institutions comprising the NHLBI’s Production Assistance for Cellular Therapies group, Moffitt is part of an exclusive group including the only NHLBI-approved facilities to produce cell-based therapies for scientific research. The facility also will manufacture human cells that will be used to help develop early-stage clinical trials to evaluate the safety and effectiveness of new therapies. These immune cell therapies include CAR T and tumor-infiltrating lymphocytes (TIL) therapies. To support the facility, the NHLBI awarded principal investigator Linda Kelley, PhD, and co-investigators James Mule, PhD, and Claudio Anasetti, MD, five years of funding with the potential to reach as high as $45 million based upon the number of projects received by the program.

VACCINE SHOWS PROMISE FOR BREAST CANCER
Brian J. Czerniecki, MD, PhD, and colleagues developed a new vaccine to help early-stage breast cancer patients with HER2 positive disease. The HER2 protein is overexpressed in nearly 25 percent of all breast cancer tumors and is associated with aggressive disease and poor prognosis. The researchers conducted a clinical trial including 54 women with HER2-expressing early-stage breast cancer and published the study in Clinical Cancer Research. The dendritic cell-based vaccine was well tolerated and effective in patients with early-stage invasive disease and even more effective in patients with early non-invasive disease.

---

NHLBI SELECTS MOFFITT AS CELL PROCESSING FACILITY
The National Heart, Lung and Blood Institute (NHLBI) selected Moffitt as a Cell Therapies Processing Facility. One of five institutions comprising the NHLBI’s Production Assistance for Cellular Therapies group, Moffitt is part of an exclusive group including the only NHLBI-approved facilities to produce cell-based therapies for scientific research. The facility also will manufacture human cells that will be used to help develop early-stage clinical trials to evaluate the safety and effectiveness of new therapies. These immune cell therapies include CAR T and tumor-infiltrating lymphocytes (TIL) therapies. To support the facility, the NHLBI awarded principal investigator Linda Kelley, PhD, and co-investigators James Mule, PhD, and Claudio Anasetti, MD, five years of funding with the potential to reach as high as $45 million based upon the number of projects received by the program.

---

MOFFITT PATHWAYS EXPAND
Moffitt’s Colon, Follicular and Papillary Thyroid Cancer Clinical Pathways went “live” in the Gastrointestinal Oncology and Endocrine clinics on April 4, bringing the number of pathways developed at Moffitt to 55. Moffitt
including Swim Across America, Callaghan Pro-Am Golf, and Moffitt raise over $1.2 million. More than 60 events, presented the scholarships with Moffitt Center Director donated $2,500 toward the initiative. Hillsborough the scholarships. Molina Healthcare of Florida generously awarded five $1,000 scholarships to students who excel in Science, Technology, Engineering, Arts and Math (STEAM) for the first time, Moffitt's Healthy KIDZ Programerving novel therapies and ultimately matching patients to the best treatment options.

MOFFITT NOW PROVIDES SERVICES AT MEMORIAL HEALTHCARE
In July, Moffitt began providing Blood and Marrow Transplant and Malignant Hematology services at Memorial Healthcare System (MHS). MHS is based in Hollywood, Florida, with facilities in Hollywood, Pembroke Pines and Miramar. MHS patients will have increased access to research, personalized medicine and innovation through distribution of Moffitt’s model of care. This relationship speaks to Moffitt’s legislative mandate to serve the citizens of Florida, as the cancer center broadens its reach, providing access to experts and delivering superior value. Moffitt’s Hugo Fernandez, MD, serves as chair of the newly formed department.

NEW STEAM ROLE MODEL SCHOLARSHIP CELEBRATES FUTURE INNOVATORS

and Buffalo Wild Wings' May promotional activities were instrumental in raising these funds to support our mission.

MILES FOR MOFFITT SPONSORED BY AUTONATION
On May 13, more than 6,500 people gathered at the USF Sun Dome to participate in this 12th annual race. Through the generous support from additional sponsors and teams, race participants, virtual runners and those who made a personal donation we raised $1.2 million (almost doubling last year’s efforts). 100% of all registration fees of this annual race go directly towards funding Moffitt researchers.

24TH ANNUAL MAGNOLIA BALL
On May 20, more than 700 guests attended the Magnolia Ball at the Marriott Waterside Hotel, where new members of Moffitt’s National Board of Advisors Scott Hamilton, Vivica A. Fox and Paul Anthony joined event Chairs Frank and Christina Capitano for an evening of entertainment and inspiration. Patient testimonials from Julie Wooley, Tracey Hyer and HSN Host Amy Morrison encouraged the guests to exceed the challenge goal. Wooley challenged the audience to match her gift of $500,000 and The Hyer Family Foundation made a donation of $1 million. By the end of the evening, the ball raised a record-setting $4 million for patient care, research and education at the cancer center.

DR. LAWRENCE INDUCTED INTO NATIONAL ACADEMY OF INVENTORS
Nicholas Lawrence, PhD, was inducted into the National Academy of Inventors for important contributions to the field of chemical biology and medicinal chemistry. Dr. Lawrence is a senior member of Moffitt’s Drug Discovery Department, and the goal of his laboratory is to design and synthesize organic molecules to act as selective anticancer agents.

DR. LARONGA NAMED PRESIDENT OF ASSOCIATION OF WOMEN SURGEONS
Christine Laronga, MD, was named president of the Association of Women Surgeons. The 1,800-member international organization committed to supporting women surgeons at various stages in their career. A surgical oncologist specializing in breast cancer at Moffitt, Dr. Laronga treats women with all levels of breast disease, is a principal investigator for several groundbreaking procedures, and she conducts basic research in proteomics.

MOFFITT RECEIVES NUMEROUS RECOGNITIONS, AWARDS
In 2016, Moffitt received numerous recognitions for key measures including employee education, development, achievement and recognition; exceptional human resources practices; diversity and inclusion; equality; work-life balance; community initiatives; exceptional patient experience and more. Key recognitions include:

• Named one of the Best and Brightest Companies To Work For®
• Named one of the Best and Brightest Companies in Wellness
• Moved up to No. 4 ranked health care facility on DiversityInc’s 2017 Top Hospitals & Health Systems list
• Designated a Leader in LGBTQ Healthcare Equality by the Human Rights Campaign, for six consecutive years
• Named a 2017 Business of Pride by Tampa Bay Business Journal for its commitment to advancing LGBTQ equality in the workplace
• Ranked No. 9 on U.S. News & World Report’s 2016 Best Hospitals for Cancer rankings
• Named one of the Working Mother 100 Best Companies
• Won a Press Ganey Guardian of Excellence Award
• Received the Health Champion Designation, as well as the Fit Friendly Worksite Gold Achievement Award, from the American Diabetes Association
• Won the Healthiest 100 Workplaces in America Award from the Corporate Health & Wellness Association
• Won the Healthiest Employer Award from the Tampa Bay Business Journal
• Named to Tampa Bay Times Top Workplaces list for sixth time
• Named to Computerworld’s 2017 list of 100 Best Places To Work in IT
• Named 2017 Nonprofit of the Year by the Tampa Bay Business Journal
• Reaccredited for the CEO Cancer Gold Standard for 2017

SUMMITT RECEIVES PEOPLE’S CHOICE AWARD
The Information Security Executive® Southeast awarded Dave Summitt, Moffitt’s chief information security officer, the People’s Choice Award for 2017. Additionally, his department’s Security Operations Center was nominated as a leading project.

DEVELOPERS OF ADVANCED POST-SECONDARY AND RESEARCH-BASED PROGRAMS TO ADVANCE CANCER CARE INFLUENCERS IN CANCER CARE MEDICAL LEADERS PIONEERS IN CANCER ADVOCACY \n
2017 HIGHLIGHTS

ACCOLADES & RECOGNITIONS 2017

2017 HIGHLIGHTS

2017 HIGHLIGHTS

2017 HIGHLIGHTS
Welcome, New Leaders

MATTHEW BEDNAR, vice president, Ambulatory Operations. In this new position, Bednar shares responsibilities with the vice president of Outpatient/chief medical officer for developing and implementing patient care delivery systems and processes in Moffitt’s outpatient settings. Previously, Bednar served in leadership roles with the Orlando Health Physicians Group for five years. Before that, he spent seven years at Emory Healthcare in Atlanta, where he held senior leadership positions in the academic section of Medicine. Bednar has a Bachelor of Science in Biological Sciences from the University of Alabama at Birmingham, and he earned a Master of Science in Biological Sciences from the University of North Carolina at Chapel Hill.

JASON FLEMING, M.D., chair, Department of Gastrointestinal Oncology. Dr. Fleming came to Moffitt from the University of Texas MD Anderson Cancer Center, where he served as professor in the Department of Surgical Oncology and chief of Pancreas Surgery and executive director of Perioperative Services. Additionally, Dr. Fleming has served as co-director of the Pancreatic Cancer Moonshot Program, member of the Dan L. Duncan Cancer Center at Baylor College of Medicine’s Data and Safety Monitoring Board (DSMB), a Pancreatic Cancer Action Network (PanCAN) Scientific and Medical Advisory board, and as a consultant for the Society of Abdominal Radiology Disease-Focused Panel. He completed his medical degree at the University of Tennessee, College of Medicine, and his clinical residency in general surgery at the University of Texas Southwestern Medical Center, Dallas. Dr. Fleming completed two fellowships: a Cancer Research Fellowship at the University of Texas Southwestern Medical Center, Hamon Center for Therapeutic Oncology, Dallas, and a clinical fellowship in Surgical Oncology at the University of Texas MD Anderson Cancer Center, Houston.

MATTHEW KUPEC, executive vice president and chief philanthropic officer. He joins the Moffitt Foundation with extensive experience in advancement and philanthropy, most recently as the vice president of Development and Marketing for HelpMeSee, an international not-for-profit corporation with a global mandate to eliminate cataract blindness. Previously, Kupec was the founder and CEO for Txit2Give, Inc., a company that uses mobile technology to help charities raise funds. He spent 20 years at the University of North Carolina, Chapel Hill, where he successfully directed the $2.3B billion Carolina First Campaign.

JOSE’ R. CONEJO-GARCIA, M.D., PH.D., co-leader of the Immunology Program and chair of the Department of Immunology. Dr. Conejo-Garcia’s research includes defining mechanisms that govern immunosuppression in the tumor microenvironment and identifying new targets for immune therapeutics, with emphasis on ovarian cancer. Before joining Moffitt, Dr. Conejo-Garcia was leader of the Tumor Microenvironment and Metastasis Program and director of Graduate Studies at The Wistar Institute in Philadelphia. He was a mentor on ovarian cancer. Before joining Moffitt, Dr. Conejo-Garcia was leader of the Tumor Microenvironment and Metastasis Program and director of Graduate Studies at The Wistar Institute in Philadelphia. He was a mentor for the Society of Abdominal Radiology Disease-Focused Panel. He completed his medical degree at the University of Tennessee, College of Medicine, and his clinical residency in general surgery at the University of Texas Southwestern Medical Center, Dallas. Dr. Fleming completed two fellowships: a Cancer Research Fellowship at the University of Texas Southwestern Medical Center, Hamon Center for Therapeutic Oncology, Dallas, and a clinical fellowship in Surgical Oncology at the University of Texas MD Anderson Cancer Center, Houston.

ELIZABETH S. DUNN, PH.D., vice president Moffitt Foundation. Dr. Dunn has more than 25 years of experience in nonprofit fundraising. She served previously as the senior associate vice chancellor of University Development at The University of North Carolina at Chapel Hill, where she managed the Central Development Office. She also served as a member of the UNC Chapel Hill Foundation, working closely with the vice chancellor for Advancement to develop and implement philanthropic strategies.

JANETTE DUQUE, PhD, chair, Biostatistics and Bioinformatics. She previously was director of Biostatistics and Informatics and associate professor at the University of Kansas Cancer Center/University of Kansas Medical Center. There she also served as the director, Biostatistics and Informatics Shared Resource and site director, K-INBRE Bioinformatics Core. Before that, she was an associate professor of Biostatistics at Mayo Clinic and previously an assistant professor, Department of Mathematics, University of Wisconsin - La Crosse. She obtained her PhD in Statistics at Iowa State University.

JULIE HALLANGER-JOHNSON, M.D., ENUC, leader, Endocrine Oncology Program. Dr. Hallanger-Johnson joined Moffitt’s Head and Neck Department and Endocrine Oncology Program in 2016. She received her MD degree from the University of North Dakota School of Medicine, and completed her residency in Internal Medicine and fellowship in Endocrinology and Metabolism at Mayo Clinic, Graduate School of Medicine. Dr. Hallanger-Johnson was an endocrinologist at Sanford Health System, Fargo, ND, for 10 years where she became chair of the Department of Endocrinology, and clinical assistant professor of Medicine at the University of North Dakota.

ROBERT WENHAM, M.D., M.S., chair, Department of Gynecologic Oncology. Dr. Wenham was recruited to Moffitt in 2004, after completing his fellowship in Gynecologic Oncology at Duke University Medical Center. He obtained his medical degree at the University of Texas Southwestern Medical School and completed his internship and residency at Harvard’s Combined Program of Obstetrics and Gynecology, Brigham and Women’s Hospital and Massachusetts General Hospital. Dr. Wenham also is an associate member of Moffitt’s Chemical Biology and Molecular Medicine Program and associate professor at the University of South Florida Morsani College of Medicine.

SHELLEY TWOROGER, PH.D., associate center director, Population Science. Dr. Tworoger comes to Moffitt from the Harvard T.H. Chan School of Public Health, where she served as associate professor in Epidemiology. She earned her undergraduate degree in Biochemistry from the University of Washington, MS and PhD degrees in Epidemiology at the Fred Hutchinson Cancer Center, and postdoctoral training at Harvard. A common thread in her research is a strong interest in optimal integration of biologic markers into epidemiologic studies, generated in large part through her former role as director of the Brigham and Women’s Hospital/Harvard Cohort Biorepository. Her extensive committee service includes serving as reviewer for the U.S. Preventive Services Task Force Ovarian Cancer Screening Report and co-chair for the Steering Committee of the Ovarian Cancer Cohort Consortium, an international collaborative group. Additionally, Dr. Tworoger serves on the editorial board for the journal Cancer Epidemiology, Biomarkers and Prevention.

DANA ROLLISON, PH.D., associate center director, Data Science. In this expanded role, Dr. Rollison will lead the newly created Data Science Division that comprises the Departments of Integrated Mathematical Oncology and Biostatistics & Bioinformatics. She will continue her responsibilities as senior member, vice president and chief data officer and will oversee Moffitt’s Collaborative Data Services Core.

We are pleased to announce several key appointments at Moffitt during 2017.
MOFFITT CANCER CENTER

LOCATIONS

MOFFITT CANCER CENTER
12902 Magnolia Drive, Tampa, Florida
Moffitt offers all levels of care for people with cancer and related diseases.

MOFFITT CANCER CENTER AT INTERNATIONAL PLAZA
4101 Jim Walter Boulevard, Tampa, Florida
Moffitt’s satellite facility near International Plaza in Tampa provides expanded and easily accessible patient services.

MOFFITT MCKINLEY OUTPATIENT CENTER
10920 North McKinley Drive, Tampa, Florida
The McKinley Center houses an outpatient surgery center, a cutaneous clinic, a breast clinic, breast imaging services, genetic counseling and more.

MOFFITT MALIGNANT HEMATOLOGY & CELLULAR THERAPY
At Memorial Healthcare System • 801 N. Flamingo Road, Pembroke Pines, Florida
In July 2017, Moffitt began providing Blood and Marrow Transplant and Malignant Hematology services at Memorial Healthcare System (MHS). MHS has facilities in Hollywood, Pembroke Pines and Miramar.

1-888-MOFFITT (1-888-663-3488) | MOFFITT.ORG

www.facebook.com/MoffittCancerCenter | twitter.com/MoffittNews

H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, AN NCI COMPREHENSIVE CANCER CENTER · TAMPA FL
© 2017 H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC All rights reserved.

Florida is the official place of business for the Moffitt Cancer Center Foundation. A copy of the official registration and financial information may be obtained from the Division of Consumer Services by calling 1-800-435-7352 toll-free within the state or online at www.800helpfla.com. Registration does not imply endorsement, approval or recommendation by the state. Florida Department of Agriculture & Consumer Services registration number CH-4675. No percentage of contributions is retained by a professional solicitor; Moffitt Cancer Center Foundation receives 100% of all donations. Your gift is tax-deductible to the extent allowed by law.